Outlook Therapeutics, Inc.

Analysis for Ticker: OTLK

Outlook Therapeutics Inc, or OTLK, is a clinical-stage company trying to sell an eye-specific version of a common cancer drug to treat retinal diseases like wet age-related macular degeneration. While it presents itself as a medical innovator, the corporate math reveals a wealth transfer mechanism that burned through 62,0$ million in net losses in 2025 alone. This is a disaster because the company is borrowing extremely expensive money just to pay off old debts while the people in charge take huge bonuses even when their medicine is rejected by the government. It is like one person who keeps taking out new credit cards with 22,0% interest to pay for an old car that does not run, all while paying themselves a salary for fixing it.